Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer

Journal of Clinical Oncology

Volumn 23, Issue 25, 2005, Pages 5943-5949

  Aghajanian, Carol ^a   Dizon, D S ^a   Sabbatini, P ^a   Raizer, J J ^a   Dupont, J ^a   Spriggs, D R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARBOPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG INHIBITION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; HUMAN; HYPERSENSITIVITY REACTION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NONHUMAN; ORTHOSTATIC DEHYDRATION; OVARY CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; RECURRENT CANCER; SINGLE DRUG DOSE; TREATMENT OUTCOME; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CARBOPLATIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PYRAZINES;

EID: 24944526723     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.16.006     Document Type: Article

References (23)

1. Goldberg AL, Stein R, Adams J: New insights into proteasome function: From Archae-bacteria to drug development. Chem Biol 2:503-508, 1995
2. Palombella VJ, Rando OJ, Goldberg AL, et al: The ubipuitin-proteasome pathway is required for processing the NF-kB1 precursor protein and the activation of NF-kB. Cell 78:773-785, 1994
3. Beg AA, Baltimore D: An essential role for NF-kB in preventing TNF-alpha-induced cell death. Science 274:782-784, 1996
4. Van Antwerp DJ, Martin SJ, Kafri T, et al: Suppression of TNF-alpha-induced apoptosis by NF-kB. Science 274:787-789, 1996
5. Wang CY, Mayo MW, Baldwin AS: TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kB. Science 274:784-787, 1996
6. Chu ZL, Mckinsey TA, Liu L, et al: Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis C-IAP2 is under NF-kB control. Proc Natl Acad Sci U S A 94: 10057-10062, 1997
7. Zetter BR: Adhesion molecules in tumor metastasis. Semin Cancer Biol 4:219-229, 1993
8. Read MA, Neish AS, Luscinskas FW, et al: The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2:493-506, 1995
9. Benyi L, Ping Dou Q: Bax degradation by the ubiquitin/proteasome- dependent pathway: Involvement in tumor survival and progression. Proc Natl Acad Sci U S A 97:3850-3855, 2000
10. An B, Goldfarb RH, Siman R: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 5:1062-1075, 1998
11. Herrmann JL, Briones F, Brisbay S, et al: Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene 17:2889-2899, 1998
12. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004
13. Ozols RF, Schwanz PE, Eifel PJ: Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma, in DeVita VT, Hellman S, Rosenberg RA (eds). Cancer: Principles and Practice of Oncology (ed 6). Baltimore, MD, Lippincott Williams and Wilkins, 2001, pp 1597-1632
14. Cusack JC: Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29:21-31, 2003
15. Yan XJ, Resales N, Aghajanian C, et al: Cisplatin induces NF-kB activity through IkB kinase dependent pathway. Proc Am Assoc Cancer Res 40:195, 1999 (abstr 1299)
16. Aghajanian C: Clinical update: Novel targets in gynecologic malignancies. Semin Oncol 31:22-26, 2004
17. Lightcap ES, McCormack TA, Pien CS, et al: Proteasome inhibition measurements: Clinical application. Clin Chem 46:673-683, 2000
18. Aghajanian C, Soignet S, Dizon DS, et al: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505-2511, 2002
19. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427, 2002
20. Papandreou CN, Daliani DD, Nix D, et al: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108-2121, 2004
21. Cusack JC Jr, Liu R, Houston M, et al: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implication for systemic nuclear factor-vB inhibitor. Cancer Res 61:3535-3540, 2001
22. Huang TT, Wuerzberger-Davis SM, Seufzer BJ, et al: NF-kB activation by a camptothecin. J Biol Chem 275:9501-9509, 2000
23. Houston MA, Liu R, Abendroth K, et al: Proteasome inhibition enhances radiosensitivity of human pancreatic cancer cells in vitro. Proc Am Assoc Cancer Res 41:709, 2000 (abstr 4505)